Archer Daniels Midland

ADM’s edge is primarily efficient scale and cost advantage from an unparalleled physical network across origination, storage, transport and processing, plus risk‑management expertise developed over decades.

These create switching frictions and service reliability for large counterparties, but they do not translate into strong price‑setting power because most end markets are commodity‑based and highly competitive. Growth initiatives in Nutrition add some intangible assets, yet profitability there has been mixed and is recovering only gradually.

Overall, we see a narrow, defendable moat vulnerable to policy and crush‑margin cycles rather than a widening, compounding moat.

Long‑run pricing power is modest. In 2024 ADM generated $85.5 billion of revenue and $5.78 billion gross profit, implying a ~6.8 percent gross margin; operating margins are low single digits and vary with crush margins, origination spreads and energy costs.

Management’s 2025 outlook commentary highlights reliance on cost control and mix rather than price to support earnings, and fourth‑quarter results reflected pressure from weaker North American crush and biofuel policy uncertainty. These dynamics indicate limited ability to push price sustainably without volume or mix offsets.

Cash generation is meaningful but cyclical. For the six months ended June 30, 2025, ADM reported operating cash flow of $3.96 billion versus $1.17 billion in 1H24, largely driven by favorable swings in inventories, receivables, and segregated investments.

While the company tightened 2025 adjusted EPS guidance to about $4.00 and noted sequential improvement in Nutrition, the core business remains exposed to weather, crop cycles, trade flows and policy. We expect variability around a mid‑cycle range rather than steady compounding.

ADM maintains solid liquidity and manageable leverage for a capital‑intensive supply chain operator.

As of June 30, 2025, cash and cash equivalents were about $1.06 billion (plus restricted/segregated balances that are not freely available), total available liquidity was approximately $10.5 billion, long‑term debt was about $7.6 billion, and short‑term debt and current maturities totaled roughly $1.6 billion.

Trailing four‑quarter adjusted ROIC was 6.7 percent in 2024 (8.3 percent adjusted), reflecting lower returns in a softer cycle, but coverage remains adequate. Maturity schedules appear well laddered.

Philosophy is pragmatic: invest in the network and selective growth while returning excess cash. FY24 buybacks were $2.33 billion; dividends totaled $985 million. In 1H25, repurchases were paused amid investigations and portfolio actions, while the dividend was raised to $0.51 per quarter, continuing a 93‑year+ streak.

Management targets $500–$750 million of multi‑year cost savings and is closing or consolidating sites to improve asset productivity. We score capital allocation as average due to mixed acquisition outcomes in Nutrition and the accounting issues that led to restatements of segment disclosures, offset by long‑term discipline and recent cost focus.

Governance took a reputational hit in 2024–2025 with Nutrition segment accounting issues, leading to an SEC/DOJ probe, a CFO change, and securities litigation.

The board appointed an external CFO (from 3M) and a new CAO (from Cargill), and the company reports that the segment‑disclosure material weakness has been remediated as of 2Q25. These are constructive steps, but the open investigations and litigation, plus return metrics below historical peaks, keep our score cautious.